Trial intelligence / Profile preview

Adjuvant Capecitabine/Oxaliplatin vs Observation in Gastric Cancer

NCT02560974Phase 3Completed

Sponsor
Roche
Start
Jun 2006
Primary completion
Nov 2012
Modality
DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
Countries
3
01

Overview

A Phase 3 trial of capecitabine, oxaliplatin in gastric adenocarcinoma, sponsored by Roche. Started Jun 2006; status: completed.

02

Drugs

capecitabineoxaliplatin
03

Conditions

gastric adenocarcinoma

Beyond the preview

Go deeper on NCT02560974.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02560974.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call